+ Watch IMMU
on My Watchlist
A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
This is my one...my ONE feel good story in my CAPS portfolio. I've followed Immunomedics for roughly six years and I've liked the direction management has taken the company in each successive year. They have never tried to mislead investors or the company, and I feel strongly their phase II trials will turn out well. Even at these price levels, I think we have discounted a poor trial result. Their cash burn rate is well within tolerance and their revenues should grow roughly 70-90% in 2008. Losses are being minimized and they are producing smaller losses than analysts expect. Here's my feel good story! Technically they always seem to find support around $1.80.NeroSagetrade
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions